Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Long-term Debt

Borrowings due after more than one year.

Immunovant, Inc.NASDAQ: IMVT

Long-term Debt · Q2 FY2027 · quarter ended Sep 2026

Long-term debt remains negative

Q2 FY2027 long-term debt was $0, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q2 FY2027, unchanged from a year earlier.
  • Long-term debt increased in 0 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearMar 2026
$0— YoY
Year agoSep 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2026
0 USD
Year-over-year change
—

Long-term Debt vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's Sep 2026 long-term debt of $0 is the 6th highest of the 11 companies compared; the peer median is $829K.
  • Long-term debt amounts to 0.0% of total assets for IMVT, versus a peer median of 0.2%.
IMVT Competitors Peer median
Long-term Debt for IMVT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TGTXTG Therapeutics, Inc.Sep 2026$745.63M +203.9%+52.6%46.8%
ZBIOZenas BioPharma, Inc.Mar 2026$350.62M ——46.9%
ANABAnaptysBio, Inc.Mar 2026$263.74M ——80.0%
QTTBQ32 Bio Inc.Mar 2026$4.75M -40.9%-11.9%7.5%
CGEMCullinan Therapeutics, Inc.Mar 2026$1.66M ——0.4%
IMVTImmunovant, Inc.Sep 2026$0 ——0.0%
TRAXFirst Tracks Biotherapeutics IncMar 2026$0 ——0.0%
ANNXAnnexon, Inc.Mar 2026$0 ——0.0%
ACRSAclaris Therapeutics, Inc.Mar 2026$0 ——0.0%
CABACabaletta Bio, Inc.Mar 2026$0 ——0.0%
IMUXImmunic, Inc.Mar 2026$0 ——0.0%
Peer median (excluding IMVT) $829K+81.5%+20.4%0.2%

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Cash & Equivalents493.82M376.53M635.37M713.97M902.11M
Short-term Investments00000
Net Receivables12.86M885K5.5M2.51M3.95M
Inventory00000
Other Current Assets0024.9M51.18M42.76M
Total Current Assets512.93M404.33M665.77M767.66M948.82M
Property, Plant & Equipment (Net)2.63M1.51M595K942K515K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00347K0553K
Other Non-current Assets0007.62M7.68M
Total Non-current Assets2.63M1.51M942K8.56M8.75M
Total Assets515.56M405.84M666.71M776.22M957.57M
Account Payables18.63M1.35M7.16M17.66M7.54M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities171K350K14.74M15.62M16.77M
Total Current Liabilities44.52M43.3M48.61M68.78M104.42M
Long-term Debt00000
Deferred Tax Liabilities00347K0553K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities1.22M47K347K0553K
Total Liabilities45.74M43.34M48.96M68.78M104.98M
Common Stock12K13K14K16K20K
Retained Earnings(355.39M)(566.35M)(825.68M)(1.24B)(1.75B)
Accumulated OCI404K852K1.91M1.46M730K
Other Stockholders Equity00000
Minority Interest00000
Total Equity469.83M362.49M617.76M707.45M852.59M
Total Debt2.36M1.22M138K98K72K
Net Debt(491.45M)(375.31M)(635.23M)(713.87M)(902.04M)

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.